Prednimustine｜Huagongshe

HuagongsheHuagongshe Chemie-Druckbericht · Nur für Forschungszwecke

HCID 34457Erstellt: 27. Oktober 2026

Prednimustine

LEO-1031 · Sterecyt · Stereocyt · NSC 171345 · NSC-134087 · Prednimustin · prednimustine · prednimustine USP/EP/BP

https://huagongshe.com/de/chemical/34457

Molekülstruktur von Prednimustine

Identifikatoren & physikalische Daten

CAS No.	29069-24-7
Summenformel	C35H45Cl2NO6
Durchschnittliche Molmasse	646,6 g/mol
Monoisotopische Masse	645,26239352 g/mol
SMILES	C[C@]12C=CC(=O)C=C1CC[C@@H]1[C@@H]2[C@@H](O)C[C@@]2(C)[C@H]1CC[C@]2(O)C(=O)COC(=O)CCCc1ccc(N(CCCl)CCCl)cc1
InChIKey	HFVNWDWLWUCIHC-GUPDPFMOSA-N
PubChem CID	34457
ChEMBL	CHEMBL2103751
ChEBI	CHEBI:82524
EC No.	249-410-3
DTXSID	DTXSID4021183

Chemische & physikalische Eigenschaften

XLogP	6
Polarare Oberfläche (TPSA)	104
H-Brücken-Donoren	2
H-Brücken-Akzeptoren	7
Frei drehbare Bindungen	13
Schwere Atome	44
Formalladung	0
Komplexität	1.140
Arzneimittel	Pharmaceuticals -> Listed in ZINC15
Color/Form	Crystals from methanol
Schmelzpunkt	163-164 °C163-164°
Optical Rotation	Optical rotation: + 92.9 degrees @ 24 °C (c = 1.06 in chloroform)
Siedepunkt	791.5±60.0 °C(Predicted)
Dichte	1.30±0.1 g/cm3(Predicted)
pKa (Säurekonstante)	12.32±0.70(Predicted)

Sicherheit & Vorschriften

Entsorgungsverfahren	SRP: At the time of review, criteria for land treatment or burial (sanitary landfill) disposal practices are subject to significant revision. Prior to implementing land disposal of waste residue (including waste sludge), consult with environmental regulatory agencies for guidance on acceptable disposal practices.
Wechselwirkungen	The purpose of this investigation was to evaluate the ability of the cysteinyl-rich protein metallothionein (MT) to protect cells against the cytotoxic effects of prednimustine, an ester of chlorambucil & prednisolone. The cells studied were MT-rich substrains of murine fibroblasts (C1 1D100) & human epithelial cells (HE100), both demonstrated in an earlier report to exhibit an approx 3-fold incr in resistance to chlorambucil compared to their parent lines (C1 1D & HE) ... . Both in cloning & in growth rate studies the MT-rich strains proved to be significantly more resistant also to prednimustine. E.g. in cloning studies D0 for C1 1D cells (D0= the dose of drug reducing survival to 1/e) was 8.7 ug/ml prednimustine, whereas D0 for C1 1D100 was 12.4 ug/ml, representing an approx 1.5-fold incr in resistance, P<0.001, t-test. Other cloning studies revealed that prednimustine had a significantly higher cell killing activity in the resistant cells than equimolar concns of its components, single or in combination. Following treatment with 3H, (14)C-prednimustine (3H in the prednisolone moiety, (14)C in the chlorambucil moiety) & subsequent gel filtration, about 40% of the cytosolic chlorambucil eluted with MT. However, no intact prednimustine was recovered in the MT fractions. The data indicate that the MT-rich cells possess increased resistance to prednimustine due to a sequestration by MT of the alkylating moiety. Since the interaction probably does not take place until after hydrolysis, it is possible that the intact conjugate may bypass this cellular defence mechanism.
Carcinogen Classification	PrednimustineGroup 3: Not classifiable as to its carcinogenicity to humansVolume 50: (1990) Pharmaceutical Drugs1989
Non-Human Toxicity Excerpts	Chlorambucil was linked to prednisolone to improve the therapeutic & toxic properties of this potent alkylating agent, which is known to induce second tumors in humans. To compare the carcinogenic potency of the linked cmpd with that of the respective individual agents & of their unlinked mixture, prednimustine (I), chlorambucil (II), prednisolone (III), chlorambucil plus prednisolone (IV), or vehicle were administered to groups of 120 female Sprague-Dawley rats for 18 months. The following doses were administered 9, 4, 5, 2 times, or once a month/subgroup of 30 rats: I, 12 mg/kg

Anwendungen & Verwendung

Verwenden

Antineoplastic.

Antidote and Emergency Treatment

Basic treatment: Establish a patent airway. Suction if necessary. Watch for signs of respiratory insufficiency and assist ventilations if needed. Administer oxygen by nonrebreather mask at 10 to 15 L/min. Monitor for pulmonary edema and treat if necessary ... . Monitor for shock and treat if necessary ... . Anticipate seizures and treat if necessary ... . For eye contamination, flush eyes immediately with water. Irrigate each eye continuously with normal saline during transport ... . Do not use emetics. For ingestion, rinse mouth and administer 5 ml/kg up to 200 ml of water for dilution if the patient can swallow, has a strong gag reflex, and does not drool ... . Cover skin burns with dry sterile dressings after decontamination ... . /Poison A and B/Advanced treatment: Consider orotracheal or nasotracheal intubation for airway control in the patient who is unconscious, has severe pulmonary edema, or is in respiratory arrest. Positive pressure ventilation techniques with a bag valve mask device may be beneficial. Monitor cardiac rhythm and treat arrhythmias as necessary ... . Start an IV with D5W /SRP: "To keep open", minimal flow rate/. Use lactated Ringer's if signs of hypovolemia are present. Watch for signs of fluid overload. Consider drug therapy for pulmonary edema ... . For hypotension with signs of hypovolemia, administer fluid cautiously. Watch for signs of fluid overload ... . Treat seizures with diazepam (Valium) ... . Use proparacaine hydrochloride to assist eye irrigation ... . /Poison A and B/